Drug Profile

Research programme: PDGFR-alpha antagonists - Sumitomo Pharma America

Alternative Names: BBI 5006

Latest Information Update: 21 Jul 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Boston Biomedical
Developer Sumitomo Pharma America
Class Small molecules
Mechanism of Action Platelet-derived growth factor alpha receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

01 Apr 2022 Sumitomo Dainippon Pharma Oncology is now called Sumitomo Pharma Oncology
01 Jul 2020 Boston Biomedical has merged with Tolero Pharmaceuticals to form Sumitomo Dainippon Pharma Oncology
30 Apr 2012 No development reported - Preclinical for Cancer in USA (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com